查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1951815

乾癬藥物市場分析及預測（至2035年）：依類型、產品類型、技術、應用、最終用戶、劑型、給藥途徑及研發階段分類

Psoriasis Drugs Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Form, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 317 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計銀屑病治療市場將從2024年的388億美元成長到2034年的1,018億美元，複合年成長率約為10.4%。銀屑病治療市場涵蓋旨在控制銀屑病（一種慢性自體免疫皮膚病）的藥物治療。該市場包括生物製藥、全身用藥和局部用藥，這些藥物專門用於減輕發炎和抑制皮膚細胞增殖。生物製藥和個人化醫療的創新正在推動市場擴張。患者群體不斷擴大、公眾意識提高以及醫療保健服務覆蓋範圍擴大，正在進一步推動市場成長，而改善患者預後和生活品質是重點。

銀屑病治療市場正經歷顯著成長，這主要得益於生物製藥和標靶治療的進步。生物製藥是表現最佳的類別，其中單株抗體和TNF-α抑制劑特別突出，它們具有更高的療效和安全性。小分子藥物，特別是PDE4抑制劑，是成長第二大的類別，因其口服給藥的便利性而日益受到歡迎。在生物製藥領域，IL-17和IL-23抑制劑已成為關鍵的細分市場，為中重度乾癬患者提供了更好的治療效果。局部治療領域依然重要，用於治療輕度乾癬的皮質類固醇和維生素D類似物保持穩定的需求。人們對個人化醫療和以患者為中心的治療方法的日益關注正在推動創新，尤其是在最佳化治療方法的聯合治療。生物相似藥的興起有望透過提高先進療法的可及性和可負擔性，進一步塑造市場格局。總體而言，在不斷發展的治療模式和未被滿足的醫療需求的推動下，該市場預計將實現強勁成長。

市場區隔
類型 生物製藥、小分子藥物、生物相似藥
產品 局部治療、全身性用藥、照光治療、生物製藥、口服治療、注射、乳膏和軟膏
科技 單株抗體、TNF抑制劑、IL-17抑制劑、IL-23抑制劑、Janus激酶抑制劑
適應症 斑塊型乾癬、水滴狀乾癬、內翻型乾癬、膿皰型乾癬、紅皮症型乾癬
最終用戶 醫院、診所、居家醫療機構、研究機構
劑型 片劑、膠囊、液體、乳膏、軟膏、凝膠、泡沫劑
給藥途徑 處方箋和非處方藥
階段 輕度乾癬、中度乾癬、重度乾癬

銀屑病治療市場競爭激烈，許多市場參與者透過策略定價和創新產品上市來擴大市場佔有率。新型生物製藥和生物相似藥的推出正在重塑市場競爭格局，並因其高效性和安全性而備受關注。各公司正透過專注於成本效益高的生產和標靶治療來策略性地定位自身，以滿足日益成長的個人化醫療需求。在這個充滿活力的市場中，以患者為中心的治療模式正在推動治療方案的顯著進步。銀屑病治療市場的競爭異常激烈，主要參與者不斷進行標竿管理以保持競爭優勢。監管，尤其是在北美和歐洲，在確保安全性和有效性標準以及塑造市場動態發揮關鍵作用。銀屑病患病率的不斷上升進一步影響市場，推動了對先進治療方法的需求。亞太地區的新興市場由於醫療保健投資和意識的不斷提高而提供了盈利的機會。儘管面臨監管障礙和高昂的研發成本等挑戰，但在創新和策略聯盟的推動下，市場前景仍然光明。

主要趨勢和促進因素：

銀屑病治療市場正經歷蓬勃發展，這主要得益於幾個關鍵趨勢和促進因素。其中一個顯著趨勢是全球銀屑病患者數量的不斷成長，從而帶動了對有效治療方法的需求。人們對銀屑病的認知不斷提高，促使更多患者尋求醫療干預，進一步擴大了市場規模。此外，生物製藥療法的進步正在革新銀屑病的治療模式。生物製藥具有標靶作用，副作用較少，因此成為醫療服務提供者的首選。生物相似藥的推出也透過提供經濟有效的替代方案，推動了市場擴張。此外，個人化醫療也備受關注，旨在提高治療效果並改善患者預後。製藥公司持續加大研發投入，開發滿足個別病患需求的客製化療法。隨著我們對銀屑病遺傳和分子因素的認知不斷加深，這一趨勢預計將持續下去。此外，監管支持和加快藥物核准也推動了市場成長。政府機構日益認知到創新治療方法的必要性，從而加快了核准流程，並促進了藥物創新。受上述因素綜合影響，預計未來幾年銀屑病治療市場將穩定成長。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 生物製藥
    • 小分子藥物
    • 生物相似藥
  • 市場規模及預測：依產品分類
    • 局部治療
    • 全身用藥
    • 照光治療
    • 生物製藥
    • 口服治療
    • 注射
    • 奶油
    • 軟膏
  • 市場規模及預測：依技術分類
    • 單株抗體
    • TNF抑制劑
    • IL-17抑制劑
    • IL-23抑制劑
    • Janus激酶抑制劑
  • 市場規模及預測：依應用領域分類
    • 斑塊型乾癬
    • 水滴狀乾癬
    • 反向型乾癬
    • 膿皰型乾癬
    • 紅皮病型乾癬
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 醫療設施
    • 居家醫療環境
    • 研究所
  • 市場規模及預測：依類型
    • 藥片
    • 膠囊
    • 液體
    • 奶油
    • 軟膏
    • 凝膠
    • 形式
  • 市場規模及預測：依管理途徑
    • 處方藥
    • 非處方藥
  • 市場規模及預測：依發展階段分類
    • 輕度乾癬
    • 中度銀屑病
    • 重度乾癬

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Dermavant Sciences
  • Arcutis Biotherapeutics
  • UCB Pharma
  • Almirall
  • Leo Pharma
  • Celgene
  • Sun Pharmaceutical Industries
  • Glenmark Pharmaceuticals
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • Amgen
  • Novartis
  • Abb Vie
  • Janssen Pharmaceuticals
  • Bristol Myers Squibb
  • Pfizer
  • Sanofi
  • Biogen
  • Merck
  • Takeda Pharmaceutical Company

第9章：關於我們

簡介目錄
Product Code: GIS32470

Psoriasis Drugs Market is anticipated to expand from $38.8 billion in 2024 to $101.8 billion by 2034, growing at a CAGR of approximately 10.4%. The Psoriasis Drugs Market encompasses pharmaceutical treatments aimed at managing psoriasis, a chronic autoimmune skin condition. This market includes biologics, systemic agents, and topical treatments tailored to reduce inflammation and slow skin cell growth. Innovations in biologic drugs and personalized medicine are propelling market expansion. Increasing prevalence, awareness, and healthcare access are further driving growth, with a focus on improving patient outcomes and quality of life.

The Psoriasis Drugs Market is experiencing significant growth, propelled by advancements in biologics and targeted therapies. The biologics segment is the top-performing category, driven by monoclonal antibodies and TNF-alpha inhibitors, which offer improved efficacy and safety profiles. Small molecules, particularly PDE4 inhibitors, are the second highest-performing segment, gaining traction due to oral administration and convenience. Within biologics, IL-17 and IL-23 inhibitors are emerging as leading sub-segments, offering enhanced outcomes for patients with moderate to severe psoriasis. The topical treatments segment remains relevant, with corticosteroids and vitamin D analogs maintaining steady demand for mild cases. The growing focus on personalized medicine and patient-centric approaches is fostering innovation, particularly in combination therapies that optimize treatment regimens. The rise of biosimilars is anticipated to further shape the market landscape, increasing accessibility and affordability of advanced therapies. Overall, the market is poised for robust expansion, driven by evolving treatment paradigms and unmet clinical needs.

Market Segmentation
TypeBiologics, Small Molecules, Biosimilars
ProductTopical Therapies, Systemic Medications, Phototherapy, Biologics, Oral Treatments, Injectables, Creams, Ointments
TechnologyMonoclonal Antibodies, TNF Inhibitors, IL-17 Inhibitors, IL-23 Inhibitors, Janus Kinase Inhibitors
ApplicationPlaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis, Erythrodermic Psoriasis
End UserHospitals, Clinics, Homecare Settings, Research Institutes
FormTablets, Capsules, Liquids, Creams, Ointments, Gels, Foams
ModePrescription, Over-the-Counter
StageMild Psoriasis, Moderate Psoriasis, Severe Psoriasis

The Psoriasis Drugs Market is characterized by a diverse array of market players, each vying for a larger share through strategic pricing and innovative product launches. The competitive landscape is shaped by the introduction of novel biologics and biosimilars, which are gaining traction due to their enhanced efficacy and safety profiles. Companies are strategically positioning themselves by focusing on cost-effective production and targeted therapies, catering to a growing demand for personalized medicine. This dynamic market is witnessing a shift towards more patient-centric approaches, driving significant advancements in treatment options. Competition within the Psoriasis Drugs Market is intense, with key players constantly benchmarking to maintain a competitive edge. Regulatory influences, particularly in North America and Europe, play a pivotal role in shaping market dynamics, ensuring safety and efficacy standards. The market is further influenced by an increasing prevalence of psoriasis, driving demand for advanced therapeutics. Emerging markets in Asia-Pacific present lucrative opportunities, with rising healthcare investments and awareness. The market's future is promising, driven by innovation and strategic collaborations, despite challenges such as regulatory hurdles and high development costs.

Geographical Overview:

The Psoriasis Drugs Market is witnessing substantial growth across various regions, each presenting unique opportunities. North America dominates the market, driven by a high prevalence of psoriasis and advanced healthcare infrastructure. The region's focus on innovative therapies and significant investment in research and development further bolsters its market leadership. Europe follows, with a strong emphasis on biologics and biosimilars, supported by robust healthcare systems and patient awareness initiatives. In Asia Pacific, the market is expanding rapidly, propelled by increasing healthcare expenditure and rising awareness of psoriasis treatments. Countries like China and India are emerging as lucrative markets due to their large patient populations and improving access to healthcare services. Latin America and the Middle East & Africa are also gaining traction, with growing healthcare investments and increasing adoption of novel therapies. Brazil and South Africa are key emerging countries, showcasing potential for growth in psoriasis drug adoption and market penetration.

The global psoriasis drugs market is intricately influenced by tariffs, geopolitical risks, and evolving supply chain dynamics. In Japan and South Korea, heightened trade tensions with Western economies prompt a strategic pivot towards self-reliance in pharmaceutical R&D and manufacturing. China, facing external pressures, accelerates its domestic production capabilities and regulatory reforms to maintain market stability. Taiwan, while pivotal in biotech innovation, navigates geopolitical uncertainties with strategic alliances. The overarching market for psoriasis drugs is witnessing robust growth, driven by increasing prevalence and advanced biologics. By 2035, the market is anticipated to flourish, contingent on harmonized regulatory frameworks and resilient supply chains. Middle East conflicts further compound global supply chains, potentially escalating raw material costs and impacting energy-dependent production processes.

Key Trends and Drivers:

The psoriasis drugs market is experiencing dynamic growth fueled by several key trends and drivers. One prominent trend is the increasing prevalence of psoriasis worldwide, which is leading to a growing demand for effective treatment options. As awareness of the condition rises, more patients are seeking medical intervention, thereby expanding the market. Furthermore, advancements in biologic therapies are revolutionizing treatment paradigms. Biologics offer targeted action with fewer side effects, making them a preferred choice among healthcare providers. The introduction of biosimilars is also driving market expansion by providing cost-effective alternatives to established biologic treatments. Additionally, there is a significant focus on personalized medicine, which is enhancing treatment efficacy and patient outcomes. Pharmaceutical companies are investing in research and development to create tailored therapies that address individual patient needs. This trend is expected to continue as the understanding of genetic and molecular factors in psoriasis deepens. Moreover, regulatory support and expedited drug approvals are facilitating market growth. Government agencies are increasingly recognizing the need for innovative treatments, leading to faster approval processes and encouraging pharmaceutical innovation. These factors collectively position the psoriasis drugs market for robust expansion in the coming years.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by Mode
  • 2.8 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Biologics
    • 4.1.2 Small Molecules
    • 4.1.3 Biosimilars
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Topical Therapies
    • 4.2.2 Systemic Medications
    • 4.2.3 Phototherapy
    • 4.2.4 Biologics
    • 4.2.5 Oral Treatments
    • 4.2.6 Injectables
    • 4.2.7 Creams
    • 4.2.8 Ointments
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Monoclonal Antibodies
    • 4.3.2 TNF Inhibitors
    • 4.3.3 IL-17 Inhibitors
    • 4.3.4 IL-23 Inhibitors
    • 4.3.5 Janus Kinase Inhibitors
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Plaque Psoriasis
    • 4.4.2 Guttate Psoriasis
    • 4.4.3 Inverse Psoriasis
    • 4.4.4 Pustular Psoriasis
    • 4.4.5 Erythrodermic Psoriasis
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Clinics
    • 4.5.3 Homecare Settings
    • 4.5.4 Research Institutes
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Tablets
    • 4.6.2 Capsules
    • 4.6.3 Liquids
    • 4.6.4 Creams
    • 4.6.5 Ointments
    • 4.6.6 Gels
    • 4.6.7 Foams
  • 4.7 Market Size & Forecast by Mode (2020-2035)
    • 4.7.1 Prescription
    • 4.7.2 Over-the-Counter
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Mild Psoriasis
    • 4.8.2 Moderate Psoriasis
    • 4.8.3 Severe Psoriasis

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Form
      • 5.2.1.7 Mode
      • 5.2.1.8 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Form
      • 5.2.2.7 Mode
      • 5.2.2.8 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Form
      • 5.2.3.7 Mode
      • 5.2.3.8 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Form
      • 5.3.1.7 Mode
      • 5.3.1.8 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Form
      • 5.3.2.7 Mode
      • 5.3.2.8 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Form
      • 5.3.3.7 Mode
      • 5.3.3.8 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Form
      • 5.4.1.7 Mode
      • 5.4.1.8 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Form
      • 5.4.2.7 Mode
      • 5.4.2.8 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Form
      • 5.4.3.7 Mode
      • 5.4.3.8 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Form
      • 5.4.4.7 Mode
      • 5.4.4.8 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Form
      • 5.4.5.7 Mode
      • 5.4.5.8 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Form
      • 5.4.6.7 Mode
      • 5.4.6.8 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Form
      • 5.4.7.7 Mode
      • 5.4.7.8 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Form
      • 5.5.1.7 Mode
      • 5.5.1.8 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Form
      • 5.5.2.7 Mode
      • 5.5.2.8 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Form
      • 5.5.3.7 Mode
      • 5.5.3.8 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Form
      • 5.5.4.7 Mode
      • 5.5.4.8 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Form
      • 5.5.5.7 Mode
      • 5.5.5.8 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Form
      • 5.5.6.7 Mode
      • 5.5.6.8 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Form
      • 5.6.1.7 Mode
      • 5.6.1.8 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Form
      • 5.6.2.7 Mode
      • 5.6.2.8 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Form
      • 5.6.3.7 Mode
      • 5.6.3.8 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Form
      • 5.6.4.7 Mode
      • 5.6.4.8 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Form
      • 5.6.5.7 Mode
      • 5.6.5.8 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Dermavant Sciences
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Arcutis Biotherapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 UCB Pharma
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Almirall
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Leo Pharma
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Celgene
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Sun Pharmaceutical Industries
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Glenmark Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Dr. Reddy's Laboratories
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Eli Lilly and Company
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Amgen
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Novartis
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Abb Vie
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Janssen Pharmaceuticals
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Bristol Myers Squibb
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Pfizer
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Sanofi
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Biogen
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Merck
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Takeda Pharmaceutical Company
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us